
  
    
      
        Synopsis_NNP
        
          Introduction_NNP
          A_DT spectrum_NN of_IN autoantibodies_NNS is_VBZ now_RB known_VBN to_TO be_VB
          specifically_RB associated_VBN with_IN RA_NNP ._. There_EX continues_VBZ to_TO be_VB
          uncertainty_NN as_IN to_TO what_WP stage_NN of_IN the_DT disease_NN each_DT of_IN these_DT
          autoantibodies_NNS develop_VBP ,_, and_CC whether_IN they_PRP are_VBP associated_VBN
          with_IN unique_JJ clinical_JJ features_NNS ._.
        
        
          Aims_VBZ
          To_TO help_VB address_VB these_DT questions_NNS ,_, a_DT spectrum_NN of_IN
          autoantibodies_NNS known_VBN to_TO be_VB associated_VBN with_IN RA_NNP in_IN a_DT cohort_NN
          of_IN patients_NNS with_IN early_JJ synovitis_NNS was_VBD evaluated_VBN ._.
        
        
          Methods_NNP
          An_DT inception_NN cohort_NN of_IN 238_CD patients_NNS having_VBG peripheral_JJ
          joint_JJ synovitis_NNS of_IN less_JJR than_IN 12_CD months_NNS duration_NN was_VBD
          evaluated_VBN clinicially_RB then_RB followed_VBN prospectively_RB for_IN 1_CD
          year_NN ._. Patients_NNS were_VBD classified_VBN as_IN having_VBG RA_NNP on_IN the_DT basis_NN
          of_IN fulfilling_VBG the_DT 1987_CD criteria_NNS ._. Serum_NNP samples_NNS collected_VBN
          at_IN the_DT time_NN of_IN the_DT initial_JJ evaluation_NN were_VBD tested_VBN for_IN
          anti-_NN Sa_NNP and_CC anti-_NN RA-_NNP 33_CD using_VBG immunoblotting_VBG ,_, and_CC to_TO
          (_( pro_FW )_) filaggrin_NN (_( AFA_NNP )_) ,_, anti-_NN CCP_NNP ,_, and_CC calpastatin_NN
          (_( anti-_NN RA-_NNP 1_LS )_) using_VBG enzyme-linked_JJ immunosorbent_NN assay_NN
          techniques_NNS ._. AKA_NNP were_VBD detected_VBN using_VBG immunoflurescence_NN on_IN
          human_JJ epidermal_NN tissue_NN ._. RF_NNP was_VBD tested_VBN by_IN nephelometry_NN ._.
          HLA-DRB_NNP 1_CD alleles_NNS were_VBD determined_VBN using_VBG sequence_NN specific_JJ
          primers_NNS ._. Initial_JJ and_CC 1_CD year_NN radiographs_NNS were_VBD evaluated_VBN
          for_IN the_DT presence_NN of_IN erosions_NNS ._.
        
        
          Results_NNS
          Of_IN the_DT 238_CD patients_NNS with_IN synovitis_NNS of_IN recent_JJ onset_NN in_IN
          the_DT cohort_NN ,_, 106_CD (_( 45_CD %_NN )_) met_VBD RA_NNP criteria_NNS ,_, 102_CD (_( 96_CD %_NN )_) of_IN whom_WP
          met_VBD the_DT criteria_NNS on_IN their_PRP$ initial_JJ visit_NN ._. Diagnoses_NNP in_IN the_DT
          remaining_VBG patients_NNS included_VBD 22_CD (_( 9_CD %_NN )_) with_IN reactive_JJ
          arthritis_NN ,_, 14_CD (_( 6_CD %_NN )_) with_IN psoriatic_JJ arthritis_NN or_CC another_DT
          form_NN of_IN spondylarthropathy_NN ,_, 11_CD (_( 5_CD %_NN )_) with_IN another_DT
          well-defined_JJ rheumatic_JJ diagnosis_NN ,_, and_CC 85_CD (_( 36_CD %_NN )_) with_IN
          undifferentiated_JJ arthritis_NN ._. The_DT RA_NNP patients_NNS were_VBD
          significantly_RB older_JJR than_IN the_DT nonRA_NN patients_NNS (_( 46_CD ±_NN 13_CD
          versus_CC 39_CD ±_NN 13_CD ;_: 
          P_NN <_NN 0_CD ._. 001_CD )_) ,_, had_VBD higher_JJR mean_NN
          swollen_JJ joint_JJ count_NN (_( 13_CD ._. 8_CD ±_NN 9_CD ._. 7_CD versus_CC 2_CD ._. 3_CD ±_NN 2_CD ._. 3_CD ;_: 
          P_NN <_NN 0_CD ._. 001_CD )_) ,_, and_CC higher_JJR
          C-_NNP reactive_JJ protein_NN (_( CRP_NNP )_) level_NN (_( 1_CD ._. 9_CD ±_NN 1_CD ._. 9_CD versus_CC 1_CD ._. 6_CD ±_NN
          2_CD ._. 4_CD ;_: 
          P_NN <_NN 0_CD ._. 01_CD )_) ._. Table_NNP 1_CD summarizes_NNS the_DT
          prevalence_NN of_IN the_DT various_JJ RA_NNP associated_VBN antibodies_NNS in_IN
          patients_NNS diagnosed_VBN as_IN having_VBG RF-positive_NNP (_( RF_NNP +_NN )_) RA_NNP ,_,
          RF-negative_NNP (_( RF-_NNP )_) RA_NNP ,_, and_CC nonRA_NN ._. Regarding_VBG the_DT
          characteristics_NNS of_IN these_DT tests_NNS ,_, RF_NNP had_VBD the_DT highest_JJS
          sensitivity_NN at_IN 66_CD %_NN ,_, and_CC all_PDT the_DT other_JJ antibodies_NNS
          individually_RB were_VBD less_JJR than_IN 50_CD %_NN sensitive_JJ ._. AFA_NNP ,_, anti-_NN Sa_NNP ,_,
          anti-_NN CCP_NNP were_VBD greater_JJR than_IN 90_CD %_NN specific_JJ for_IN RA_NNP ,_, while_IN RF_NNP
          and_CC AKA_NNP were_VBD 80_CD -_: 90_CD %_NN specific_JJ ,_, and_CC anti-_NN RA-_NNP 33_CD and_CC
          anti-_NN RA-_NNP 1_CD was_VBD not_RB specific_JJ for_IN this_DT diagnosis_NN ._. The_DT data_NNS
          further_JJ indicate_VBP that_IN adding_VBG any_DT one_CD of_IN AFA_NNP ,_, AKA_NNP ,_,
          anti-_NN Sa_NNP ,_, or_CC anti-_NN CCP_NNP to_TO RF_NNP increases_VBZ the_DT specificity_NN for_IN
          RA_NNP from_IN 80_CD to_TO 90_CD %_NN ._. In_IN the_DT absence_NN of_IN RF_NNP ,_, the_DT presence_NN of_IN
          one_CD or_CC more_JJR of_IN these_DT antibodies_NNS carried_VBD a_DT sensitivity_NN of_IN
          only_RB 31_CD %_NN for_IN RF-_NNP RA_NNP ,_, with_IN anti-_NN Sa_NNP being_VBG the_DT most_RBS specific_JJ
          at_IN 98_CD %_NN ._. Overall_RB ,_, there_EX was_VBD a_DT high_JJ degree_NN of_IN correlation_NN
          between_IN AFA_NNP ,_, AKA_NNP ,_, anti-_NN Sa_NNP or_CC anti-_NN CCP_NNP ,_, this_DT being_VBG highest_JJS
          between_IN anti-_NN Sa_NNP and_CC anti-_NN CCP_NNP (_( odds_NNS ratio_NN ,_, 13_CD ._. 3_LS ;_: 
          P_NN <_NN 0_CD ._. 001_CD )_) ._. Despite_IN this_DT high_JJ
          level_NN of_IN correlation_NN ,_, of_IN the_DT 101_CD patients_NNS who_WP were_VBD
          positive_JJ for_IN at_IN least_JJS one_CD of_IN these_DT four_CD autoantibodies_NNS ,_,
          57_CD %_NN were_VBD positive_JJ for_IN only_RB one_CD ,_, suggesting_VBG considerable_JJ
          variability_NN in_IN individual_JJ reactivity_NN patterns_NNS ._.
          RA_NNP has_VBZ been_VBN shown_VBN in_IN multiple_JJ populations_NNS to_TO be_VB
          associated_VBN with_IN HLA-DRB_NNP 1_CD alleles_NNS encoding_VBG for_IN the_DT shared_VBN
          epitope_NN (_( SE_NNP )_) ._. In_IN this_DT study_NN ,_, as_IN illustrated_VBN in_IN Table_NNP 2_CD ,_,
          the_DT presence_NN of_IN each_DT of_IN these_DT autoantibodies_NNS was_VBD
          significantly_RB associated_VBN with_IN having_VBG two_CD shared_VBN epitope_NN
          alleles_NNS ,_, even_RB when_WRB only_RB the_DT RA_NNP patients_NNS were_VBD
          considered_VBN ._.
          Patients_NNS with_IN anti-_NN Sa_NNP antibodies_NNS were_VBD predominantly_RB
          male_JJ (_( 61_CD %_NN versus_CC 28_CD %_NN ;_: 
          P_NN <_NN 0_CD ._. 01_CD )_) ,_, had_VBD significantly_RB
          higher_JJR swollen_JJ joint_JJ counts_VBZ (_( 18_CD ±_NN 12_CD versus_CC 13_CD ±_NN 9_CD ;_: 
          P_NN =_SYM 0_CD ._. 02_CD )_) ,_, and_CC higher_JJR CRP_NNP levels_NNS
          (_( 2_CD ._. 6_CD ±_NN 3_CD mg_NN /_NN dl_NN versus_CC 1_CD ._. 6_CD ±_NN 1_CD ._. 4_CD mg_NN /_NN dl_NN ;_: 
          P_NN =_SYM 0_CD ._. 03_CD )_) at_IN the_DT initial_JJ visit_NN ._.
          Despite_IN subsequently_RB begin_VB treated_VBN with_IN significantly_RB
          higher_JJR doses_NNS of_IN prednisone_NN (_( 4_CD ._. 8_CD ±_NN 6_CD ._. 0_CD mg_NN /_NN day_NN versus_CC 1_CD ._. 8_CD ±_NN
          3_CD ._. 3_CD mg_NN /_NN day_NN ;_: 
          P_NN <_NN 0_CD ._. 01_CD )_) ,_, and_CC more_JJR disease_NN
          modifying_VBG antirheumatic_JJ drug_NN therapy_NN (_( 1_CD ._. 4_LS ±_NN 0_CD ._. 8_CD versus_CC
          0_CD ._. 9_CD ±_NN 0_CD ._. 7_CD disease_NN modifying_VBG antirheumatic_JJ drugs_NNS ;_: 
          P_NN <_NN 0_CD ._. 01_CD )_) ,_, the_DT anti-_NN Sa-positive_NNP
          RA_NNP patients_NNS had_VBD a_DT higher_JJR frequency_NN of_IN erosions_NNS than_IN the_DT
          rest_NN of_IN the_DT RA_NNP patients_NNS (_( 60_CD %_NN versus_CC 33_CD %_NN ;_: 
          P_NN =_SYM 0_CD ._. 03_CD )_) ._. Neither_DT RF_NNP nor_CC SE_NNP were_VBD
          associated_VBN with_IN the_DT disease_NN severity_NN measures_NNS ,_, and_CC
          analyses_NNS evaluating_VBG all_PDT the_DT other_JJ autoantibodies_NNS failed_VBD
          to_TO reveal_VB a_DT similar_JJ trend_NN ._.
        
        
          Discussion_NNP
          Despite_IN a_DT well-documented_JJ lack_NN of_IN specificity_NN ,_, RF_NNP
          continues_VBZ to_TO be_VB a_DT central_JJ part_NN of_IN the_DT definition_NN of_IN RA_NNP ,_,
          primarily_RB because_IN of_IN its_PRP$ favourable_JJ sensitivity_NN profile_NN ._.
          In_IN our_PRP$ cohort_NN ,_, RF_NNP had_VBD a_DT sensitivity_NN of_IN 66_CD %_NN ,_, a_DT specificity_NN
          of_IN 87_CD %_NN ,_, and_CC an_DT overall_JJ accuracy_NN of_IN 78_CD %_NN for_IN the_DT diagnosis_NN
          of_IN RA_NNP ._. AFA_NNP ,_, anti-_NN Sa_NNP ,_, anti-_NN CCP_NNP were_VBD all_DT highly_RB specific_JJ
          for_IN this_DT diagnosis_NN ,_, and_CC when_WRB any_DT of_IN them_PRP were_VBD present_JJ in_IN
          conjunction_NN with_IN RF_NNP ,_, the_DT specificity_NN for_IN RA_NNP approached_VBD
          100_CD %_NN ._. Potentially_NNP of_IN more_JJR importance_NN to_TO the_DT clinician_NN is_VBZ
          the_DT diagnostic_JJ value_NN of_IN these_DT antibodies_NNS when_WRB RF_NNP is_VBZ not_RB
          detectable_JJ ._. Our_PRP$ data_NNS indicate_VBP that_IN only_RB 31_CD %_NN of_IN RF-_NNP RA_NNP
          patients_NNS had_VBD any_DT of_IN AKA_NNP ,_, AFA_NNP ,_, anti-_NN Sa_NNP or_CC anti-_NN CCP_NNP ,_, and_CC
          that_DT anti-_NN Sa_NNP was_VBD the_DT most_RBS specific_JJ for_IN this_DT diagnosis_NN ._.
          This_DT modest_JJ level_NN of_IN sensitivity_NN suggests_VBZ that_DT testing_NN
          for_IN this_DT spectrum_NN of_IN autoantibodies_NNS carries_VBZ little_JJ
          advantage_NN over_IN RF_NNP alone_RB in_IN diagnosing_VBG early_JJ RA_NNP ._.
          AFA_NNP ,_, AKA_NNP ,_, and_CC antiperinuclear_NN factor_NN (_( APF_NNP )_) have_VBP all_DT
          been_VBN proposed_VBN to_TO identify_VB a_DT common_JJ antigen_NN present_JJ in_IN the_DT
          skin_NN protein_NN (_( pro_FW )_) filaggrin_NN ._. It_PRP has_VBZ continued_VBN to_TO be_VB
          puzzling_JJ why_WRB a_DT skin_NN antigen_NN would_MD be_VB targeted_VBN relatively_RB
          specifically_RB in_IN a_DT disorder_NN that_WDT is_VBZ primarily_RB articular_NN ._. A_DT
          potential_JJ explanation_NN for_IN this_DT may_MD relate_VB to_TO the_DT
          demonstration_NN that_DT citrulline_NN appears_VBZ to_TO be_VB an_DT essential_JJ
          constituent_NN of_IN the_DT antigenic_JJ determinants_NNS recognized_VBN by_IN
          AKA_NNP ,_, APF_NNP ,_, and_CC AFA_NNP ._. The_DT citrulline_NN rich_JJ (_( pro_FW )_) filaggrin_NN
          molecule_NN makes_VBZ an_DT ideal_JJ substrate_NN for_IN detecting_VBG this_DT
          reactivity_NN ._. Moreover_RB ,_, the_DT SA_NNP antigen_NN ,_, which_WDT ,_, unlike_IN
          (_( pro_FW )_) filaggrin_NN ,_, is_VBZ detectable_JJ in_IN rheumatoid_NN synovium_NN ,_, has_VBZ
          recently_RB been_VBN shown_VBN to_TO also_RB be_VB citrullinated_JJ ._. It_PRP is_VBZ thus_RB
          possible_JJ that_IN AKA_NNP ,_, AFA_NNP ,_, APE_NNP ,_, and_CC anti-_NN Sa_NNP all_DT recognize_VBP
          one_CD or_CC more_RBR citrullinated_JJ antigens_NNS ._. Despite_IN this_DT
          possibility_NN ,_, the_DT modest_JJ degree_NN of_IN concordance_NN between_IN
          them_PRP in_IN individual_JJ patient_NN sera_NN suggests_VBZ that_IN it_PRP is_VBZ
          unlikely_JJ that_IN a_DT single_JJ antigen_NN is_VBZ involved_VBN in_IN generating_VBG
          these_DT responses_NNS ._.
          This_DT study_NN provides_VBZ evidence_NN suggesting_VBG that_DT anti-_NN Sa_NNP
          antibodies_NNS appear_VBP to_TO be_VB a_DT marker_NN for_IN a_DT subset_NN of_IN early_JJ RA_NNP
          patients_NNS whose_WP$ disease_NN may_MD be_VB more_RBR severe_JJ and_CC erosive_JJ ._.
          Moreover_RB ,_, it_PRP was_VBD determined_VBN that_DT anti-_NN Sa_NNP ,_, AFA_NNP ,_, and_CC
          anti-_NN CCP_NNP were_VBD all_DT highly_RB associated_VBN with_IN SE_NNP ,_, particularly_RB
          two_CD copies_NNS ._. We_PRP examined_VBD a_DT spectrum_NN of_IN potential_JJ RA_NNP
          severity_NN indicators_NNS including_VBG the_DT number_NN of_IN swollen_JJ
          joints_NNS ,_, CRP_NNP level_NN ,_, and_CC presence_NN of_IN early_JJ radiographic_JJ
          erosions_NNS ._. Our_PRP$ data_NNS indicate_VBP that_DT anti-_NN Sa_NNP was_VBD more_RBR highly_RB
          associated_VBN with_IN these_DT measures_NNS of_IN RA_NNP severity_NN than_IN any_DT
          other_JJ parameter_NN ,_, including_VBG the_DT most_JJS accepted_VBN prognostic_JJ
          indicators_NNS ,_, RF_NNP and_CC SE_NNP ._.
          In_IN conclusion_NN ,_, it_PRP is_VBZ demonstrated_VBN that_IN antibodies_NNS
          directed_VBN against_IN putatively_RB citrullinated_JJ antigens_NNS
          including_VBG SA_NNP ,_, filaggrin_NN ,_, keratin_NN ,_, and_CC CCP_NNP are_VBP the_DT most_RBS
          specific_JJ for_IN RA_NNP ,_, and_CC are_VBP detectable_JJ early_RB in_IN the_DT disease_NN
          course_NN ._. It_PRP will_MD be_VB of_IN interest_NN to_TO find_VB out_IN whether_IN the_DT
          cumulative_JJ prevalence_NN of_IN specific_JJ autoantibody_NN subsets_NNS
          tends_VBZ to_TO increase_VB over_IN time_NN ,_, as_IN this_DT would_MD suggest_VB that_IN
          the_DT mechanisms_NNS underlying_VBG the_DT development_NN of_IN these_DT
          reactivities_NNS continue_VBP to_TO evolve_VB over_IN the_DT course_NN of_IN the_DT
          arthropathy_NN ._.
        
      
      
        Introduction_NNP
        Autoantibodies_NNP can_MD be_VB detected_VBN in_IN a_DT spectrum_NN of_IN
        rheumatic_JJ diseases_NNS where_WRB they_PRP may_MD be_VB highly_RB associated_VBN with_IN
        distinct_JJ clinical_JJ syndromes_NNS ._. These_DT are_VBP often_RB helpful_JJ for_IN
        diagnosis_NN ,_, and_CC to_TO some_DT extent_NN ,_, prognosis_NN ._. In_IN RA_NNP ,_, RF_NNP is_VBZ
        detected_VBN in_IN 70_CD -_: 80_CD %_NN of_IN patients_NNS with_IN established_VBN disease_NN ,_,
        and_CC is_VBZ an_DT integral_JJ part_NN of_IN the_DT definition_NN of_IN this_DT disorder_NN ._.
        AKA_NNP ,_, APF_NNP ,_, AFA_NNP ,_, and_CC anti-_NN Sa_NNP have_VBP all_DT been_VBN shown_VBN to_TO be_VB
        associated_VBN with_IN RA_NNP ,_, and_CC appear_VB to_TO be_VB more_RBR specific_JJ than_IN RF_NNP
        for_IN this_DT disease_NN [_NN 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ,_, 6_CD ,_, 7_CD ,_, 8_CD ,_, 9_CD ]_NN ._. Anti-_NNP RA-_NNP 33_CD ,_,
        [_NN 10_CD ,_, 11_CD ,_, 12_CD ]_NN and_CC anti-_NN RA-_NNP 1_CD [_NN 13_CD ]_NN have_VBP also_RB been_VBN shown_VBN to_TO
        be_VB prevalent_JJ in_IN RA_NNP patient_NN populations_NNS ,_, but_CC not_RB specific_JJ
        for_IN this_DT disease_NN ._.
        There_EX is_VBZ an_DT evolving_VBG understanding_NN of_IN the_DT antigens_NNS to_TO
        which_WDT these_DT RA_NNP associated_VBN antibodies_NNS are_VBP directed_VBN ,_, although_IN
        their_PRP$ ultimate_JJ pathogenic_JJ role_NN ,_, if_IN any_DT ,_, continues_VBZ to_TO be_VB
        unclear_JJ ._. AKA_NNP ,_, APF_NNP ,_, and_CC AFA_NNP identify_VBP epitopes_NNS carried_VBN by_IN
        keratin_NN ,_, profilaggrin_NN and_CC filaggrin_NN ,_, respectively_RB [_NN 3_CD ,_, 6_CD ,_,
        14_CD ,_, 15_CD ]_NN ._. These_DT proteins_NNS follow_VBP a_DT common_JJ post-translational_JJ
        pathway_NN ,_, which_WDT involves_VBZ a_DT peptidyl-arginine_JJ to_TO citrulline_NN
        deimination_NN ._. This_DT modification_NN appears_VBZ to_TO be_VB central_JJ to_TO
        specific_JJ antigenicity_NN ,_, giving_VBG rise_NN to_TO epitopes_NNS recognized_VBN
        by_IN sera_NN from_IN RA_NNP patients_NNS [_NN 16_CD ,_, 17_CD ]_NN ._. Anti-_NNP Sa_NNP antibodies_NNS are_VBP
        directed_VBN towards_IN an_DT unknown_JJ antigen_NN that_WDT is_VBZ abundant_JJ in_IN
        placental_NN tissue_NN and_CC rheumatoid_NN synovium_NN [_NN 7_CD ]_NN ._.
        Interestingly_RB ,_, the_DT Sa_NNP antigen_NN also_RB appears_VBZ to_TO be_VB
        citrullinated_JJ [_NN 18_CD ]_NN ._. Anti-_NNP RA-_NNP 33_CD antibodies_NNS recognize_VBP the_DT A_DT 2_CD
        protein_NN ,_, an_DT antigen_NN found_VBD in_IN the_DT heterogeneous_JJ
        ribonucleoprotein_NN of_IN the_DT splicosome_NN [_NN 19_CD ]_NN ._. Anti-_NNP RA-_NNP 1_CD
        antibodies_NNS are_VBP directed_VBN towards_IN domains_NNS 3_CD and_CC 4_CD of_IN
        calpastatin_NN ,_, the_DT natural_JJ inhibitor_NN of_IN calpains_NNS ,_, which_WDT are_VBP
        members_NNS of_IN the_DT cysteine_NN proteinases_NNS that_WDT have_VBP been_VBN
        implicated_VBN in_IN articular_NN damage_NN [_NN 13_CD ]_NN ._.
        This_DT spectrum_NN of_IN autoantibodies_NNS has_VBZ been_VBN evaluated_VBN
        primarily_RB in_IN cohorts_NNS of_IN patients_NNS with_IN well-established_JJ RA_NNP ._.
        A_DT number_NN of_IN important_JJ questions_NNS are_VBP unresolved_JJ regarding_VBG
        the_DT stage_NN of_IN the_DT disease_NN at_IN which_WDT each_DT of_IN these_DT antibodies_NNS
        arise_VBP ,_, and_CC whether_IN indeed_RB some_DT may_MD antedate_NN the_DT clinical_JJ
        expression_NN of_IN this_DT disorder_NN ._. The_DT fact_NN that_IN RF_NNP ,_, AKA_NNP or_CC APF_NNP
        could_MD sometimes_RB antedate_NN the_DT appearance_NN of_IN clinical_JJ RA_NNP by_IN
        several_JJ years_NNS has_VBZ been_VBN reported_VBN [_NN 20_CD ,_, 21_CD ,_, 22_CD ]_NN ._. Anti-_NNP Sa_NNP ,_, AFA_NNP
        and_CC anti-_NN RA-_NNP 33_CD have_VBP been_VBN reported_VBN to_TO be_VB present_JJ in_IN early_JJ RA_NNP
        patients_NNS ,_, although_IN the_DT cohorts_NNS studied_VBN have_VBP generally_RB been_VBN
        small_JJ ,_, and_CC the_DT clinical_JJ characterization_NN of_IN the_DT patients_NNS
        not_RB detailed_JJ [_NN 1_CD ,_, 8_CD ,_, 9_CD ,_, 23_CD ,_, 24_CD ]_NN ._. Anticyclic_NNP citrullinated_JJ
        peptide_NN (_( anti-_NN CCP_NNP )_) has_VBZ recently_RB been_VBN evaluated_VBN in_IN a_DT cohort_NN
        of_IN patients_NNS with_IN early_JJ synovitis_NNS ,_, and_CC was_VBD found_VBN to_TO be_VB more_RBR
        specific_JJ than_IN RF_NNP for_IN early_JJ RA_NNP ,_, while_IN having_VBG comparable_JJ
        sensitivity_NN [_NN 25_CD ]_NN ._.
        Recently_RB ,_, the_DT clinical_JJ features_NNS and_CC human_JJ leukocyte_NN
        antigen_NN (_( HLA_NNP )_) associations_NNS of_IN a_DT well-characterized_JJ cohort_NN
        of_IN patients_NNS with_IN synovitis_NNS of_IN recent_JJ onset_NN were_VBD presented_VBN [_NN
        26_CD ]_NN ._. In_IN the_DT current_JJ study_NN ,_, we_PRP sought_VBD to_TO determine_VB the_DT
        prevalence_NN and_CC diagnostic_JJ value_NN of_IN the_DT RA_NNP associated_VBN
        autoantibodies_NNS in_IN this_DT heterogeneous_JJ cohort_NN of_IN patients_NNS
        with_IN early_JJ synovitis_NNS ._. Sera_NNP obtained_VBD within_IN 12_CD months_NNS of_IN
        symptom_NN onset_NN were_VBD tested_VBN for_IN these_DT antibodies_NNS ,_, and_CC their_PRP$
        presence_NN was_VBD related_VBN to_TO disease_NN features_NNS and_CC subsequent_JJ
        clinical_JJ course_NN over_IN a_DT 1_CD year_NN period_NN ._. Our_PRP$ data_NNS indicate_VBP
        that_IN AFA_NNP ,_, anti-_NN Sa_NNP ,_, and_CC anti-_NN CCP_NNP are_VBP all_DT highly_RB specific_JJ for_IN
        early_JJ RA_NNP ,_, but_CC demonstrate_VB only_RB a_DT modest_JJ degree_NN of_IN
        concordance_NN in_IN the_DT sera_NN of_IN individual_JJ patients_NNS ._. Anti-_NNP Sa_NNP
        identifies_VBZ a_DT subset_NN of_IN male_JJ RA_NNP patients_NNS with_IN severe_JJ
        disease_NN ._.
      
      
        Methods_NNP
        
          Patients_NNS
          Two_CD hundred_CD and_CC thirty-eight_JJ patients_NNS were_VBD recruited_VBN
          to_TO an_DT early_JJ synovitis_NNS study_VBP at_IN the_DT National_NNP Institutes_NNPS of_IN
          Health_NNP (_( protocol_NN 94_CD -_: AR-_NNP 194_CD )_) ._. The_DT study_NN patients_NNS had_VBD
          persistent_JJ synovitis_NNS (_( >_NN 6_CD weeks_NNS )_) of_IN at_IN least_JJS one_CD
          peripheral_JJ joint_NN ,_, which_WDT had_VBD been_VBN present_JJ for_IN less_JJR than_IN 1_CD
          year_NN ._. Patients_NNS with_IN traumatic_JJ ,_, septic_JJ ,_, and_CC crystal_NN
          induced_VBD arthritis_NN were_VBD specifically_RB excluded_VBN ._.
          Patients_NNS underwent_VBD a_DT complete_JJ clinical_JJ evaluation_NN ._. The_DT
          number_NN of_IN swollen_JJ joints_NNS was_VBD determined_VBN by_IN evaluating_VBG for_IN
          the_DT presence_NN of_IN effusion_NN and_CC /_NN or_CC synovial_NN thickening_VBG in_IN 66_CD
          peripheral_JJ joints_NNS (_( hips_NNS were_VBD excluded_VBN )_) ._. Patients_NNS were_VBD
          then_RB followed_VBN clinically_RB over_IN a_DT 1_CD year_NN period_NN ._. Routine_NNP
          laboratory_NN data_NNS were_VBD obtained_VBN on_IN each_DT visit_NN ,_, including_VBG an_DT
          evaluation_NN of_IN acute_JJ phase_NN reactants_NNS ._. Anteroposterior_NNP and_CC
          lateral_NN radiographs_NNS of_IN the_DT hands_NNS and_CC feet_NNS were_VBD either_CC
          available_JJ for_IN evaluation_NN or_CC obtained_VBN at_IN the_DT time_NN of_IN
          assessment_NN ._. A_DT second_RB set_NN of_IN radiographs_NNS was_VBD obtained_VBN at_IN
          the_DT 1_CD year_NN visit_NN ._. All_DT radiographs_NNS were_VBD evaluated_VBN for_IN the_DT
          presence_NN of_IN erosions_NNS ._. Although_IN a_DT proportion_NN of_IN the_DT
          radiographs_NNS were_VBD felt_VBN to_TO have_VB '_POS possible_JJ '_POS or_CC
          '_POS questionable_JJ '_POS erosions_NNS ,_, only_RB patients_NNS with_IN definite_JJ
          erosions_NNS on_IN either_DT set_NN of_IN radiographs_NNS were_VBD included_VBN in_IN
          the_DT definition_NN of_IN erosions_NNS ._. At_IN the_DT completion_NN of_IN the_DT year_NN
          of_IN observation_NN ,_, patients_NNS who_WP were_VBD diagnosed_VBN as_IN having_VBG RA_NNP
          had_VBD all_DT met_VBN the_DT 1987_CD American_NNP College_NNP of_IN Rheumatology_NNP
          (_( ACR_NNP )_) criteria_NNS [_NN 27_CD ]_NN on_IN at_IN least_JJS one_CD visit_NN ._. If_IN a_DT patient_NN
          had_VBD met_VBN ACR_NNP criteria_NNS ,_, but_CC with_IN follow_VB up_RB was_VBD
          unequivocally_RB diagnosed_VBN as_IN having_VBG another_DT
          well-characterized_JJ rheumatic_JJ disease_NN ,_, this_DT individual_NN was_VBD
          not_RB included_VBN in_IN the_DT definition_NN of_IN RA_NNP ._.
        
        
          Detection_NNP of_IN autoantibodies_NNS
          IgM_NNP RF_NNP was_VBD measured_VBN by_IN nephelometry_NN ,_, and_CC a_DT level_NN
          >_NN 20_CD IU_NNP /_NN ml_NN was_VBD considered_VBN positive_JJ ._. Anti-_NNP Sa_NNP antibodies_NNS
          were_VBD detected_VBN by_IN immunoblot_NN ,_, as_RB previously_RB described_VBD [_NN
          7_CD ]_NN ._. A_DT partially_RB purified_JJ preparation_NN of_IN placental_NN Sa_NNP
          antigen_NN was_VBD provided_VBN by_IN one_CD of_IN the_DT authors_NNS (_( HAM_NNP )_) ,_, and_CC the_DT
          western_JJ blot_NN assay_NN performed_VBN blindly_RB by_IN another_DT (_( GS_NNP )_) ._.
          RA-_NNP 33_CD was_VBD detected_VBN using_VBG immunoblot_NN ,_, as_IN described_VBN
          previously_RB [_NN 19_CD ]_NN ._. Filaggrin_NNP was_VBD obtained_VBN from_IN human_JJ
          epidermis_NNS and_CC purified_JJ using_VBG reversed_VBN phase_NN
          high-performance_JJ liquid_JJ chromatography_NN ._. After_IN covalently_RB
          coupling_NN to_TO 96_CD -_: well_RB plates_NNS ,_, AFA_NNP were_VBD detected_VBN by_IN
          enzyme-linked_JJ immunosorbent_NN assay_NN (_( ELISA_NNP )_) as_RB previously_RB
          described_VBD [_NN 1_CD ,_, 5_CD ]_NN ._. The_DT cutoff_NN level_NN for_IN positivity_NN (_( OD_NNP ,_,
          0_CD ._. 15_CD )_) was_VBD determined_VBN on_IN the_DT basis_NN of_IN results_NNS of_IN sera_NN from_IN
          100_CD middle-aged_JJ (_( 40_CD -_: 65_CD years_NNS )_) blood_NN donors_NNS ._. Antibodies_NNP to_TO
          CCP_NNP were_VBD evaluated_VBN after_IN generating_VBG a_DT cyclic_JJ peptide_NN from_IN
          linear_JJ citrulline_NN containing_VBG peptides_NNS ,_, by_IN substituting_VBG
          serine_NN residues_NNS by_IN cysteine_NN ._. Anti-_NNP CCP_NNP were_VBD detected_VBN using_VBG
          ELISA_NNP as_RB previously_RB described_VBD with_IN the_DT linear_JJ peptides_NNS [_NN
          17_CD ]_NN ._. Control_NN peptides_NNS had_VBD an_DT unmodified_JJ arginine_NN rather_RB
          than_IN citrulline_NN ._. The_DT cutoff_NN level_NN for_IN positivity_NN (_( OD_NNP ,_,
          0_CD ._. 3_LS )_) was_VBD determined_VBN on_IN the_DT basis_NN of_IN generating_NN 100_CD %_NN
          specificity_NN for_IN RA_NNP in_IN previous_JJ assays_NNS using_VBG local_JJ normal_JJ
          controls_NNS ._. AKA_NNP were_VBD detected_VBN using_VBG immunoflurescence_NN ._.
          Sections_NNP of_IN human_JJ breast_NN epidermis_NNS were_VBD used_VBN ,_, and_CC the_DT
          slides_NNS were_VBD read_VBN independently_RB by_IN two_CD observers_NNS (_( AR_NNP and_CC
          CZ_NNP )_) ._. Any_DT slides_NNS in_IN which_WDT the_DT observers_NNS did_VBD not_RB agree_VB were_VBD
          reread_NN ,_, and_CC a_DT consensus_NN agreed_VBD ._. In_IN all_DT cases_NNS ,_, the_DT
          detected_VBD autoantibodies_NNS were_VBD of_IN the_DT IgG_NNP class_NN ._. The_DT
          results_NNS were_VBD not_RB corrected_VBN for_IN total_JJ IgG_NNP levels_NNS ._.
        
        
          HLA_NNP typing_VBG
          HLA-DR_NNP typing_VBG was_VBD done_VBN by_IN the_DT molecular_JJ polymerase_NN
          chain_NN reaction-sequence_JJ specific_JJ primers_NNS methods_NNS using_VBG
          specific_JJ oligonucleotide_NN sequences_NNS as_RB primers_NNS as_RB
          previously_RB described_VBD [_NN 28_CD ]_NN ._. Shared_NNP epitope_NN (_( SE_NNP )_) alleles_NNS
          included_VBD DRB_NNP 1_CD *_NN 0101_CD ,_, *_NN 0102_CD ,_, *_NN 0401_CD ,_, *_NN 0404_CD ,_, *_NN 0405_CD ,_, *_NN 0408_CD ,_,
          *_NN 1001_CD ,_, *_NN 1402_CD ._.
        
        
          Statistical_NNP analysis_NN
          Patient_NNP groups_NNS were_VBD compared_VBN using_VBG analysis_NN of_IN
          variance_NN of_IN the_DT Kruskal-_NNP Wallis_NNP test_NN for_IN continuous_JJ
          variables_NNS ,_, and_CC using_VBG the_DT Chi-squared_NNP test_NN for_IN
          proportions_NNS ._. The_DT significance_NN level_NN for_IN associations_NNS
          between_IN individual_JJ autoantibodies_NNS and_CC HLA-DRB_NNP 1_CD alleles_NNS
          was_VBD adjusted_VBN for_IN multiple_JJ comparisons_NNS using_VBG the_DT
          Bonferroni_NNP method_NN ._. Statistical_NNP analysis_NN was_VBD performed_VBN
          using_VBG Epi_NNP Info_NNP statistical_JJ software_NN (_( Center_NNP for_IN Disease_NNP
          Control_NNP ,_, Atlanta_NNP ,_, GA_NNP ,_, USA_NNP :_:
          http_NN :_: /_NN /_NN www_NN ._. cdc_NN ._. gov_NN /_NN epo_NN /_NN epi_NN /_NN epiinfo_NN ._. htm_NN )_) ._.
        
      
      
        Results_NNS
        
          Prevalence_NNP of_IN the_DT autoantibodies_NNS in_IN the_DT patient_NN
          cohort_NN
          Table_NNP 1_CD indicates_VBZ the_DT prevalence_NN of_IN a_DT spectrum_NN of_IN known_VBN
          autoantibodies_NNS and_CC of_IN the_DT RA_NNP associated_VBN antibodies_NNS in_IN
          patients_NNS diagnosed_VBN as_IN having_VBG RF_NNP +_NN RA_NNP ,_, RF-_NNP RA_NNP ,_, and_CC nonRA_NN ._.
          In_IN total_JJ ,_, 87_CD patients_NNS were_VBD RF-positive_NNP ,_, 17_CD of_IN whom_WP did_VBD
          not_RB meet_VB RA_NNP criteria_NNS any_DT point_NN during_IN the_DT study_NN period_NN ,_,
          and_CC were_VBD classified_VBN as_IN having_VBG undifferentiated_JJ arthritis_NN ._.
          Antinuclear_NNP antibodies_NNS were_VBD detected_VBN in_IN 65_CD /_NN 238_CD (_( 27_CD %_NN )_)
          patients_NNS ,_, and_CC were_VBD of_IN comparable_JJ prevalence_NN in_IN the_DT
          patient_NN groups_NNS ._. Less_JJR than_IN 10_CD %_NN of_IN the_DT patients_NNS in_IN all_DT
          groups_NNS demonstrated_VBD antibodies_NNS to_TO SSA_NNP ,_, SSB_NNP ,_, dsDNA_NN ,_,
          ribonucleoprotein_NN (_( RNP_NNP )_) ,_, and_CC Sm_NNP ._. Of_IN the_DT RA_NNP associated_VBN
          antibodies_NNS tested_VBN ,_, AFA_NNP ,_, anti-_NN Sa_NNP ,_, anti-_NN CCP_NNP ,_, and_CC AKA_NNP were_VBD
          all_DT significantly_RB more_RBR prevalent_JJ in_IN the_DT RF_NNP +_NN RA_NNP group_NN
          compared_VBN with_IN either_DT the_DT RF-_NNP RA_NNP group_NN or_CC the_DT nonRA_NN group_NN ._.
          Anti-_NNP RA-_NNP 1_CD antibodies_NNS were_VBD detected_VBN in_IN 35_CD %_NN of_IN the_DT cohort_NN
          with_IN no_DT significant_JJ difference_NN between_IN the_DT groups_NNS ._.
          Anti-_NNP RA-_NNP 33_CD antibodies_NNS were_VBD detected_VBN in_IN three_CD patients_NNS in_IN
          the_DT cohort_NN ._. Please_VB note_NN ,_, the_DT prevalence_NN of_IN anti-_NN Sa_NNP
          antibodies_NNS was_VBD significantly_RB higher_JJR in_IN the_DT RF-_NNP RA_NNP group_NN
          compared_VBN with_IN the_DT nonRA_NN group_NN (_( 14_CD %_NN versus_CC 2_CD %_NN ;_: 
          P_NN <_NN 0_CD ._. 01_CD )_) ,_, but_CC there_EX were_VBD no_DT
          differences_NNS in_IN the_DT prevalence_NN of_IN the_DT other_JJ autoantibodies_NNS
          between_IN these_DT two_CD patient_NN groups_NNS ._. In_IN total_JJ ,_, 90_CD /_NN 106_CD (_( 85_CD %_NN )_)
          of_IN the_DT RA_NNP patients_NNS and_CC 75_CD /_NN 132_CD (_( 57_CD %_NN )_) of_IN the_DT nonRA_NN patients_NNS
          had_VBD at_IN least_JJS one_CD of_IN the_DT RA_NNP associated_VBN antibodies_NNS ._.
        
        
          Diagnostic_NNP value_NN of_IN antibodies_NNS for_IN RA_NNP
          The_DT diagnostic_JJ value_NN of_IN the_DT individual_JJ antibodies_NNS for_IN
          RA_NNP is_VBZ shown_VBN in_IN Table_NNP 3_CD ._. RF_NNP had_VBD the_DT highest_JJS sensitivity_NN at_IN
          66_CD %_NN ,_, and_CC all_PDT the_DT other_JJ antibodies_NNS were_VBD individually_RB less_JJR
          than_IN 50_CD %_NN sensitive_JJ ._. AFA_NNP ,_, anti-_NN Sa_NNP and_CC anti-_NN CCP_NNP were_VBD
          greater_JJR than_IN 90_CD %_NN specific_JJ for_IN RA_NNP ,_, while_IN RF_NNP and_CC AKA_NNP were_VBD
          80_CD -_: 90_CD %_NN specific_JJ ,_, and_CC anti-_NN RA-_NNP 1_CD was_VBD not_RB specific_JJ for_IN this_DT
          diagnosis_NN ._. The_DT data_NNS further_JJ indicate_VBP that_IN adding_VBG any_DT one_CD
          of_IN AFA_NNP ,_, AKA_NNP ,_, anti-_NN Sa_NNP ,_, or_CC anti-_NN CCP_NNP to_TO RF_NNP increases_VBZ the_DT
          specificity_NN for_IN RA_NNP from_IN 80_CD to_TO 90_CD %_NN ._. In_IN the_DT absence_NN of_IN RF_NNP ,_,
          the_DT presence_NN of_IN one_CD or_CC more_JJR of_IN these_DT antibodies_NNS carried_VBD a_DT
          sensitivity_NN of_IN only_RB 31_CD %_NN for_IN RF-_NNP RA_NNP ,_, with_IN anti-_NN Sa_NNP being_VBG
          the_DT most_RBS specific_JJ at_IN 98_CD %_NN ._. At_IN the_DT completion_NN of_IN the_DT study_NN ,_,
          of_IN the_DT 37_CD /_NN 132_CD (_( 28_CD %_NN )_) nonRA_NN patients_NNS positive_JJ for_IN one_CD of_IN
          AFA_NNP ,_, AKA_NNP ,_, anti-_NN Sa_NNP ,_, or_CC anti-_NN CCP_NNP ,_, 12_CD had_VBD some_DT form_NN of_IN
          spondylarthropathy_NN ,_, 4_CD had_VBD a_DT connective_JJ tissue_NN disease_NN ,_,
          and_CC 21_CD continued_VBD with_IN a_DT diagnosis_NN of_IN '_POS undifferentiated_JJ
          arthritis_NN '_'' ._.
        
        
          Correlation_NNP between_IN antibodies_NNS in_IN patient_NN
          sera_NN
          Previous_JJ studies_NNS have_VBP generally_RB suggested_VBN a_DT high_JJ
          degree_NN of_IN correlation_NN in_IN RA_NNP patient_NN sera_NN between_IN AFA_NNP ,_,
          AKA_NNP ,_, anti-_NN CCP_NNP ,_, and_CC anti-_NN Sa_NNP ._. We_PRP tested_VBD the_DT correlation_NN
          between_IN these_DT antibodies_NNS in_IN the_DT patient_NN sera_NN ._. The_DT
          correlation_NN was_VBD highest_JJS between_IN anti-_NN CCP_NNP and_CC anti-_NN Sa_NNP
          [_NN odds_NNS ratio_NN (_( OR_NNP )_) ,_, 13_CD ._. 3_LS ;_: 
          P_NN <_NN 0_CD ._. 001_CD )_) ,_, and_CC lowest_JJS between_IN
          anti-_NN Sa_NNP and_CC AKA_NNP (_( OR_NNP ,_, 2_CD ._. 4_CD ;_: 
          P_NN =_SYM 0_CD ._. 09_CD )_) ._. In_IN total_JJ ,_, 101_CD patients_NNS
          had_VBD at_IN least_JJS one_CD of_IN the_DT four_CD antibodies_NNS ,_, 64_CD %_NN of_IN whom_WP had_VBD
          RA_NNP ._. Of_IN these_DT 101_CD patients_NNS ,_, 57_CD were_VBD in_IN fact_NN positive_JJ for_IN
          only_RB one_CD antibody_NN (_( AKA_NNP =_SYM 20_CD ,_, AFA_NNP =_SYM 12_CD ,_, anti-_NN Sa_NNP =_SYM 6_CD ,_,
          anti-_NN CCP_NNP =_SYM 19_CD )_) ._. Only_RB seven_CD patients_NNS were_VBD positive_JJ for_IN all_DT
          four_CD antibodies_NNS ._.
          Seropositivity_NNP for_IN anti-_NN CCP_NNP and_CC AFA_NNP was_VBD determined_VBN on_IN
          the_DT basis_NN of_IN an_DT ELISA_NNP cut-off_JJ level_NN as_IN described_VBN in_IN the_DT
          Methods_NNP section_NN ._. The_DT relationship_NN between_IN the_DT titers_NNS of_IN
          these_DT two_CD antibodies_NNS ,_, and_CC between_IN each_DT of_IN them_PRP and_CC RF_NNP ,_,
          was_VBD examined_VBN ._. There_EX was_VBD a_DT significant_JJ correlation_NN in_IN the_DT
          titers_NNS of_IN anti-_NN CCP_NNP and_CC AFA_NNP in_IN individual_JJ sera_NN (_( 
          r_LS =_SYM 0_CD ._. 46_CD ;_: 
          P_NN <_NN 0_CD ._. 001_CD )_) ._. Titers_NNP of_IN both_DT
          anti-_NN CCP_NNP and_CC AFA_NNP were_VBD not_RB correlated_JJ with_IN RF_NNP titers_NNS ._. When_WRB
          only_RB anti-_NN CCP-positive_NNP patients_NNS were_VBD examined_VBN ,_, the_DT mean_NN
          CCP_NNP titer_NN was_VBD significantly_RB higher_JJR in_IN the_DT RF-positive_NNP
          patients_NNS (_( 
          n_NN =_SYM 44_CD )_) compared_VBN with_IN the_DT
          RF-negative_NNP patients_NNS (_( 
          n_NN =_SYM 10_CD )_) (_( 1_CD ._. 07_CD ±_NN 0_CD ._. 55_CD versus_CC 0_CD ._. 6_CD ±_NN
          0_CD ._. 34_CD ;_: 
          P_NN =_SYM 0_CD ._. 01_CD )_) ._. A_DT similar_JJ tread_VB was_VBD seen_VBN
          with_IN AFA_NNP ,_, although_IN this_DT did_VBD not_RB reach_VB statistical_JJ
          significance_NN ._. Of_IN note_NN also_RB ,_, the_DT mean_NN RF_NNP titer_NN for_IN
          RF-positive_NNP patients_NNS who_WP did_VBD not_RB meet_VB RA_NNP criteria_NNS did_VBD not_RB
          differ_VB from_IN the_DT RF-positive_NNP patients_NNS who_WP were_VBD diagnosed_VBN
          as_IN having_VBG RA_NNP (_( 202_CD ±_NN 172_CD versus_CC 207_CD ±_NN 169_CD ;_: 
          P_NN =_SYM not_RB significant_JJ )_) ._.
        
        
          RF_NNP ,_, Sa_NNP ,_, AFA_NNP ,_, and_CC CCP_NNP are_VBP highly_RB associated_VBN with_IN
          shared_VBN epitope_NN in_IN early_JJ RA_NNP
          RA_NNP has_VBZ been_VBN shown_VBN in_IN multiple_JJ populations_NNS to_TO be_VB
          associated_VBN with_IN HLA-DR_NNP alleles_NNS encoding_VBG for_IN the_DT SE_NNP ._. We_PRP
          sought_VBD to_TO determine_VB if_IN specific_JJ autoantibodies_NNS were_VBD
          particularly_RB associated_VBN with_IN SE_NNP alleles_NNS in_IN our_PRP$ cohort_NN ._.
          These_DT data_NNS are_VBP presented_VBN in_IN Table_NNP 2_CD ._. Overall_RB ,_, the_DT SE_NNP
          alleles_NNS were_VBD highly_RB associated_VBN with_IN the_DT diagnosis_NN of_IN RA_NNP
          (_( OR_NNP 3_CD ._. 0_CD ;_: 
          P_NN <_NN 0_CD ._. 0001_CD )_) ._. RF_NNP ,_, AFA_NNP ,_, anti-_NN Sa_NNP ,_,
          and_CC anti-_NN CCP_NNP were_VBD all_DT associated_VBN with_IN SE_NNP alleles_NNS ,_,
          particularly_RB two_CD copies_NNS ._. Interestingly_RB ,_, 6_CD /_NN 6_CD patients_NNS with_IN
          *_NN 0101_CD /_NN *_NN 0401_CD were_VBD positive_JJ for_IN at_IN least_JJS one_CD of_IN these_DT
          autoantibodies_NNS ._.
        
        
          Anti-_NNP Sa_NNP antibodies_NNS identify_VBP a_DT male_JJ predominant_NN
          subset_NN of_IN RA_NNP patients_NNS with_IN severe_JJ disease_NN
          Table_NNP 4_CD demonstrates_VBZ that_IN ,_, in_IN comparison_NN with_IN all_DT other_JJ
          RA_NNP patients_NNS ,_, RA_NNP patients_NNS with_IN anti-_NN Sa_NNP antibodies_NNS were_VBD
          predominantly_RB male_JJ (_( 61_CD %_NN versus_CC 28_CD %_NN ;_: 
          P_NN <_NN 0_CD ._. 01_CD )_) ,_, had_VBD significantly_RB
          higher_JJR swollen_JJ joint_JJ counts_VBZ (_( 18_CD ±_NN 12_CD versus_CC 13_CD ±_NN 9_CD ;_: 
          P_NN =_SYM 0_CD ._. 02_CD )_) ,_, and_CC higher_JJR CRP_NNP levels_NNS
          (_( 2_CD ._. 6_CD ±_NN 3_CD mg_NN /_NN dl_NN versus_CC 1_CD ._. 6_CD ±_NN 1_CD ._. 4_CD mg_NN /_NN dl_NN ;_: 
          P_NN =_SYM 0_CD ._. 03_CD )_) at_IN the_DT initial_JJ visit_NN ._.
          Despite_IN subsequently_RB being_VBG treated_VBN with_IN significantly_RB
          higher_JJR doses_NNS of_IN prednisone_NN (_( 4_CD ._. 8_CD ±_NN 6_CD ._. 0_CD mg_NN /_NN day_NN versus_CC 1_CD ._. 8_CD ±_NN
          3_CD ._. 3_CD mg_NN /_NN day_NN ;_: 
          P_NN <_NN 0_CD ._. 01_CD )_) ,_, and_CC more_JJR disease_NN
          modifying_VBG antirheumatic_JJ drug_NN therapy_NN (_( 1_CD ._. 4_LS ±_NN 0_CD ._. 8_CD versus_CC
          0_CD ._. 9_CD ±_NN 0_CD ._. 7_CD disease_NN modifying_VBG antirheumatic_JJ drugs_NNS ;_: 
          P_NN <_NN 0_CD ._. 01_CD )_) ,_, the_DT anti-_NN Sa-positive_NNP
          RA_NNP patients_NNS had_VBD a_DT higher_JJR frequency_NN of_IN erosions_NNS that_IN the_DT
          rest_NN of_IN the_DT RA_NNP patients_NNS (_( 60_CD %_NN versus_CC 33_CD %_NN ;_: 
          P_NN =_SYM 0_CD ._. 03_CD )_) ._. Table_NNP 4_CD further_JJ indicates_VBZ
          that_IN neither_DT RF_NNP nor_CC SE_NNP was_VBD associated_VBN with_IN the_DT disease_NN
          severity_NN measures_NNS ,_, and_CC analyses_NNS evaluating_VBG all_PDT the_DT other_JJ
          autoantibodies_NNS failed_VBD to_TO reveal_VB a_DT similar_JJ trend_NN (_( data_NNS not_RB
          shown_VBN )_) ._. Of_IN interest_NN ,_, only_RB six_CD RA_NNP patients_NNS demonstrated_VBD
          the_DT presence_NN of_IN nodules_NNS ,_, and_CC this_DT feature_NN was_VBD more_RBR
          associated_JJ with_IN RF_NNP and_CC SE_NNP than_IN with_IN anti-_NN Sa_NNP ._. Analysis_NNP of_IN
          the_DT nonRA_NN patients_NNS did_VBD not_RB reveal_VB any_DT clinically_RB
          meaningful_JJ associations_NNS with_IN any_DT of_IN the_DT
          autoantibodies_NNS ._.
        
      
      
        Discussion_NNP
        A_DT cohort_NN of_IN patients_NNS with_IN synovitis_NNS of_IN recent_JJ onset_NN was_VBD
        evaluated_VBN and_CC we_PRP sought_VBD to_TO determine_VB the_DT prevalence_NN and_CC
        potential_JJ clinical_JJ utility_NN of_IN a_DT spectrum_NN of_IN autoantibodies_NNS
        that_WDT has_VBZ been_VBN shown_VBN to_TO be_VB associated_VBN with_IN RA_NNP ._. To_TO date_NN ,_, most_JJS
        of_IN the_DT studies_NNS evaluating_VBG these_DT antibodies_NNS have_VBP been_VBN in_IN
        patients_NNS with_IN established_VBN ,_, well-characterized_JJ disease_NN ,_, and_CC
        their_PRP$ prevalence_NN and_CC diagnostic_JJ value_NN in_IN patients_NNS with_IN
        early_JJ inflammatory_JJ arthritis_NN has_VBZ not_RB been_VBN defined_VBN ._. Our_PRP$
        study_NN evaluated_VBD patients_NNS within_IN a_DT few_JJ months_NNS of_IN the_DT onset_NN
        of_IN synovitis_NNS ,_, and_CC then_RB followed_VBN them_PRP for_IN a_DT 1_CD year_NN period_NN to_TO
        determine_VB the_DT best_JJS clinical_JJ diagnosis_NN ._. In_IN particular_JJ ,_, we_PRP
        sought_VBD to_TO determine_VB how_WRB sensitive_JJ and_CC specific_JJ each_DT of_IN the_DT
        antibodies_NNS ,_, alone_RB and_CC in_IN combination_NN ,_, were_VBD for_IN early_JJ RA_NNP ._. We_PRP
        utilized_JJ the_DT accepted_VBN definition_NN of_IN RA_NNP using_VBG the_DT 1987_CD ACR_NNP
        criteria_NNS [_NN 27_CD ]_NN ._. Of_IN note_NN ,_, a_DT large_JJ epidemiologic_JJ study_NN of_IN
        patients_NNS with_IN early_JJ inflammatory_JJ arthritis_NN found_VBD that_IN the_DT
        proportion_NN of_IN patients_NNS who_WP met_VBD the_DT ACR_NNP criteria_NNS increased_VBN
        if_IN the_DT criteria_NNS were_VBD applied_VBN cumulatively_RB over_IN a_DT 5_CD year_NN
        period_NN [_NN 29_CD ]_NN ._. Although_IN the_DT duration_NN of_IN follow_VB up_RB in_IN this_DT
        study_NN was_VBD shorter_JJR ,_, we_PRP found_VBD that_IN almost_RB all_DT of_IN the_DT patients_NNS
        who_WP had_VBD met_VBN the_DT RA_NNP criteria_NNS at_IN the_DT completion_NN of_IN the_DT study_NN
        period_NN had_VBD done_VBN so_RB on_IN their_PRP$ initial_JJ visit_NN ._.
        Despite_IN a_DT well-documented_JJ lack_NN of_IN specificity_NN ,_, RF_NNP
        continues_VBZ to_TO be_VB a_DT central_JJ part_NN of_IN the_DT definition_NN of_IN RA_NNP ,_,
        primarily_RB because_IN of_IN its_PRP$ favorable_JJ sensitivity_NN profile_NN ._. In_IN
        our_PRP$ cohort_NN ,_, RF_NNP had_VBD a_DT sensitivity_NN of_IN 66_CD %_NN ,_, a_DT specificity_NN of_IN
        87_CD %_NN ,_, and_CC an_DT overall_JJ accuracy_NN of_IN 78_CD %_NN for_IN the_DT diagnosis_NN of_IN
        RA_NNP ._. AFA_NNP ,_, anti-_NN Sa_NNP and_CC anti-_NN CCP_NNP were_VBD all_DT highly_RB specific_JJ for_IN
        this_DT diagnosis_NN ,_, and_CC when_WRB any_DT of_IN them_PRP were_VBD present_JJ in_IN
        conjunction_NN with_IN RF_NNP ,_, the_DT specificity_NN for_IN RA_NNP approached_VBD
        100_CD %_NN ._. Potentially_NNP of_IN more_JJR importance_NN to_TO the_DT clinician_NN is_VBZ
        the_DT diagnostic_JJ value_NN of_IN these_DT antibodies_NNS when_WRB RF_NNP is_VBZ not_RB
        detectable_JJ ._. Our_PRP$ data_NNS indicate_VBP that_IN only_RB 31_CD %_NN of_IN RF-_NNP RA_NNP
        patients_NNS had_VBD any_DT of_IN AKA_NNP ,_, AFA_NNP ,_, anti-_NN Sa_NNP or_CC anti-_NN CCP_NNP ,_, and_CC that_DT
        anti-_NN Sa_NNP was_VBD the_DT most_RBS specific_JJ for_IN this_DT diagnosis_NN ._. This_DT
        modest_JJ level_NN of_IN sensitivity_NN suggests_VBZ that_DT testing_NN for_IN this_DT
        spectrum_NN of_IN autoantibodies_NNS carries_VBZ little_JJ advantages_NNS over_IN
        RF_NNP alone_RB in_IN diagnosing_VBG early_JJ RA_NNP ._.
        This_DT study_NN provides_VBZ evidence_NN suggesting_VBG that_DT anti-_NN Sa_NNP
        anti-bodies_JJ appear_VB to_TO be_VB a_DT marker_NN for_IN a_DT subset_NN of_IN early_JJ RA_NNP
        patients_NNS whose_WP$ disease_NN may_MD be_VB more_RBR severe_JJ and_CC erosive_JJ ._.
        These_DT data_NNS are_VBP consistent_JJ with_IN observations_NNS in_IN a_DT French_NNP RA_NNP
        cohort_NN ,_, where_WRB anti-_NN Sa_NNP and_CC SE_NNP were_VBD associated_VBN with_IN severe_JJ
        radiographic_JJ erosions_NNS [_NN 9_CD ]_NN ._. Indeed_RB ,_, it_PRP was_VBD determined_VBN that_DT
        anti-_NN Sa_NNP ,_, AFA_NNP ,_, and_CC anti-_NN CCP_NNP were_VBD all_DT highly_RB associated_VBN with_IN
        SE_NNP ,_, particularly_RB two_CD copies_NNS ._. We_PRP examined_VBD a_DT spectrum_NN of_IN
        potential_JJ RA_NNP severity_NN indicators_NNS including_VBG the_DT number_NN of_IN
        swollen_JJ joints_NNS ,_, CRP_NNP level_NN ,_, and_CC presence_NN of_IN early_JJ
        radiographic_JJ erosions_NNS ._. Our_PRP$ data_NNS indicate_VBP that_DT anti-_NN Sa_NNP was_VBD
        more_RBR highly_RB associated_VBN with_IN these_DT measures_NNS of_IN RA_NNP severity_NN
        than_IN any_DT other_JJ parameter_NN ,_, including_VBG the_DT most_JJS accepted_VBN
        prognostic_JJ indicators_NNS ,_, RF_NNP and_CC SE_NNP ._. In_IN particular_JJ ,_, there_EX was_VBD
        a_DT significantly_RB higher_JJR prevalence_NN of_IN radiographic_JJ erosions_NNS
        in_IN the_DT anti-_NN Sa-positive_NNP RA_NNP patients_NNS compared_VBN with_IN the_DT rest_NN
        of_IN the_DT RA_NNP population_NN ,_, despite_IN the_DT fact_NN that_IN the_DT
        anti-_NN Sa-positive_NNP patients_NNS had_VBD received_VBN significantly_RB higher_JJR
        doses_NNS of_IN prednisone_NN and_CC more_JJR disease_NN modifying_VBG
        antirheumatic_JJ drug_NN therapy_NN ._. Interestingly_RB ,_, the_DT
        anti-_NN Sa-positive_NNP subset_NN in_IN this_DT cohort_NN was_VBD strikingly_RB
        predominated_JJ by_IN males_NNS (_( 61_CD %_NN of_IN Sa-positive_NNP versus_CC 28_CD %_NN of_IN
        Sa-negative_NNP RA_NNP patients_NNS ;_: 
        P_NN <_NN 0_CD ._. 001_CD )_) ._. It_PRP has_VBZ recently_RB been_VBN
        shown_VBN that_IN ,_, in_IN comparison_NN with_IN female_JJ RA_NNP patients_NNS ,_, male_JJ RA_NNP
        patients_NNS tended_VBD to_TO develop_VB erosions_NNS earlier_RBR in_IN the_DT disease_NN
        course_NN [_NN 30_CD ]_NN ._. The_DT finding_VBG that_DT anti-_NN Sa_NNP antibodies_NNS are_VBP
        associated_VBN both_DT with_IN male_JJ gender_NN and_CC with_IN severe_JJ early_JJ RA_NNP
        further_JJ emphasizes_VBZ the_DT importance_NN of_IN gender_NN differences_NNS in_IN
        the_DT clinical_JJ expression_NN of_IN this_DT heterogeneous_JJ disease_NN ._.
        AFA_NNP ,_, AKA_NNP ,_, and_CC APF_NNP have_VBP been_VBN proposed_VBN to_TO all_DT identify_VBP a_DT
        common_JJ antigen_NN present_JJ in_IN the_DT skin_NN protein_NN (_( pro_FW )_) filaggrin_NN [_NN
        1_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ,_, 6_CD ]_NN ._. It_PRP has_VBZ continued_VBN to_TO be_VB puzzling_JJ why_WRB a_DT skin_NN
        antigen_NN would_MD be_VB targeted_VBN relatively_RB specifically_RB in_IN a_DT
        disorder_NN that_WDT is_VBZ primarily_RB articular_NN ._. A_DT potential_JJ
        explanation_NN for_IN this_DT may_MD relate_VB to_TO the_DT demonstration_NN that_DT
        citrulline_NN appears_VBZ to_TO be_VB an_DT essential_JJ constituent_NN of_IN the_DT
        antigenic_JJ determinants_NNS recognized_VBN by_IN AKA_NNP ,_, APF_NNP ,_, and_CC AFA_NNP [_NN
        16_CD ,_, 17_CD ]_NN ._. The_DT citrulline_NN rich_JJ (_( pro_FW )_) filaggrin_NN molecule_NN makes_VBZ
        an_DT ideal_JJ substrate_NN for_IN detecting_VBG this_DT reactivity_NN ._. Moreover_RB ,_,
        the_DT Sa_NNP antigen_NN ,_, which_WDT ,_, unlike_IN (_( pro_FW )_) filaggrin_NN ,_, is_VBZ detectable_JJ
        in_IN rheumatoid_NN synovium_NN ,_, has_VBZ recently_RB also_RB been_VBN shown_VBN to_TO be_VB
        citrullinated_JJ [_NN 18_CD ]_NN ._. It_PRP is_VBZ thus_RB possible_JJ that_IN AKA_NNP ,_, AFA_NNP ,_,
        APF_NNP ,_, and_CC anti-_NN Sa_NNP all_DT recognize_VBP one_CD or_CC more_RBR citrullinated_JJ
        antigens_NNS ._. As_IN with_IN previous_JJ studies_NNS ,_, the_DT current_JJ study_NN
        documents_VBZ a_DT good_JJ overall_JJ correlation_NN between_IN these_DT
        antibodies_NNS ._. Nevertheless_RB ,_, the_DT data_NNS clearly_RB indicate_VBP that_DT
        reactivity_NN to_TO CCP_NNP does_VBZ not_RB capture_VB that_IN complete_JJ spectrum_NN
        of_IN AFA_NNP ,_, AKA_NNP ,_, and_CC anti-_NN Sa_NNP reactivity_NN ._. Indeed_RB ,_, it_PRP has_VBZ been_VBN
        shown_VBN that_IN 56_CD %_NN of_IN patients_NNS who_WP were_VBD positive_JJ for_IN one_CD or_CC
        more_JJR of_IN these_DT antibodies_NNS were_VBD positive_JJ for_IN only_RB one_CD ,_, and_CC
        that_IN only_RB 7_CD %_NN of_IN these_DT patients_NNS were_VBD positive_JJ for_IN all_DT of_IN
        them_PRP ._. Similarly_RB ,_, previous_JJ studies_NNS evaluating_VBG AKA_NNP ,_, APF_NNP ,_, and_CC
        AFA_NNP have_VBP shown_VBN varying_VBG degrees_NNS of_IN discordance_NN in_IN the_DT
        seropositivity_NN of_IN individual_JJ patient_NN sera_NN [_NN 3_CD ,_, 4_CD ,_, 5_CD ,_, 14_CD ]_NN ._.
        Moreover_RB ,_, there_EX was_VBD a_DT spectrum_NN of_IN reactivity_NN patterns_NNS seen_VBN
        when_WRB RA_NNP sera_NN were_VBD tested_VBN against_IN various_JJ citrulline_NN
        containing_VBG peptides_NNS [_NN 17_CD ]_NN ._. Together_RB ,_, these_DT data_NNS are_VBP most_RBS
        consistent_JJ with_IN the_DT hypothesis_NNS that_IN individual_JJ RA_NNP patients_NNS
        respond_VBP to_TO unique_JJ antigenic_JJ determinants_NNS ,_, that_WDT may_MD
        preferentially_RB be_VB citrullinated_JJ ,_, but_CC that_WDT are_VBP likely_JJ
        distinct_JJ from_IN those_DT of_IN targeted_VBN by_IN other_JJ RA_NNP patients_NNS ._.
        It_PRP was_VBD surprising_JJ to_TO discover_VB that_DT anti-_NN RA-_NNP 33_CD antibodies_NNS
        were_VBD all_DT but_CC absent_JJ in_IN this_DT cohort_NN of_IN patients_NNS ,_,
        particularly_RB in_IN view_NN of_IN the_DT previously_RB reported_VBN prevalence_NN
        of_IN 20_CD -_: 40_CD %_NN in_IN other_JJ RA_NNP cohorts_NNS [_NN 10_CD ,_, 11_CD ,_, 12_CD ]_NN ._. This_DT antibody_NN
        was_VBD reported_VBN to_TO have_VB a_DT prevalence_NN of_IN only_RB 6_CD %_NN in_IN a_DT Finnish_JJ
        cohort_NN of_IN early_JJ RA_NNP patients_NNS [_NN 24_CD ]_NN ._. It_PRP should_MD be_VB pointed_VBN out_RP
        that_IN the_DT testing_NN for_IN anti-_NN RA-_NNP 33_CD ,_, including_VBG that_WDT performed_VBD
        in_IN the_DT current_JJ study_NN ,_, was_VBD all_DT performed_VBN in_IN the_DT same_JJ
        laboratory_NN (_( GS_NNP )_) ._. The_DT reasons_NNS for_IN this_DT discrepancy_NN are_VBP
        unclear_JJ ,_, and_CC may_MD represent_VB inherent_JJ differences_NNS in_IN the_DT
        populations_NNS studied_VBN ._. Alternatively_RB ,_, it_PRP is_VBZ possible_JJ that_IN the_DT
        development_NN of_IN anti-_NN RA-_NNP 33_CD reactivity_NN increases_NNS as_IN the_DT
        diseases_NNS progresses_VBZ ._. Longitudinal_NNP follow_VB up_RB of_IN early_JJ RA_NNP
        cohorts_NNS ,_, such_JJ as_IN the_DT present_JJ one_CD ,_, will_MD help_VB to_TO further_VB
        clarify_VB this_DT issue_NN ._.
        In_IN the_DT current_JJ study_NN ,_, it_PRP was_VBD demonstrated_VBN that_IN
        antibodies_NNS directed_VBN against_IN putatively_RB citrullinated_JJ
        antigens_NNS including_VBG Sa_NNP ,_, filaggrin_NN ,_, keratin_NN ,_, and_CC CCP_NNP are_VBP the_DT
        most_RBS specific_JJ for_IN RA_NNP ,_, and_CC are_VBP detectable_JJ early_RB in_IN the_DT
        disease_NN course_NN ._. It_PRP will_MD be_VB of_IN interest_NN to_TO find_VB out_IN whether_IN
        the_DT cumulative_JJ prevalence_NN of_IN specific_JJ autoantibody_NN subsets_NNS
        tends_VBZ to_TO increase_VB over_IN time_NN ,_, as_IN this_DT would_MD suggest_VB that_IN the_DT
        mechanisms_NNS underlying_VBG the_DT development_NN of_IN these_DT reactivities_NNS
        continue_VBP to_TO evolve_VB over_IN the_DT course_NN of_IN the_DT arthropathy_NN ._.
      
    
  
